The SETH Group's primary focus is helping people diagnosed with the most deadly form of brain cancer, glioblastoma multiforme (GBM). Additionally, the group hopes to apply any treatment discoveries made to other forms of cancer. GBM is the most common form of brain cancer but more than 25 years of research in pharmaceutical anti-cancer agents has had little impact on patient survival. SETH Group President, Garret Yount, Ph.D., and Medical Director, Yifang Qian, M.D., Ph.D., were awarded one of the first major grants from the U.S. Government's National Institutes of Health (NIH) to explore whether compounds derived from Chinese herbs might be helpful against GBM tumor cells. They were also awarded one of the first NIH grants to assess the efficacy of energy medicine or biofield therapies using GBM cell models. The findings of these studies serve as the foundation for SETH's lead research projects. These projects seek to: > Explore the potential for Chinese herbal extracts to enhance cancer cell response to radiation > Develop autologous delivery systems for gene therapy > Test efficacy of biofield devices as chemosensitizers > Investigate potential anti-cancer effects of medicinal cannabis (see Featured Experiment) Through their professional affiliations, SETH scientists utilize state-of-the-art medical research technology including gene expression profiling, genomic and proteomic analysis systems. This technology enables SETH scientists to employ the strictest standards when evaluating novel therapies. The SETH group also utilizes an advanced computerized time-lapse microscope which allows the group to study the responsiveness of cancer and normal cells in their optimum environment. This focus on living, functioning cells is rare among medical researchers. Research executed by SETH scientists follows accepted cancer research practices and the Group expects their success in publishing results in peer-reviewed scientific journals to continue.